Last mentioned: Mar 15, 2026
Revenue Milestone Target
Target date for achieving a $6 billion annual revenue run rate.
Strategic Migration
Veeva accelerates the transition of customers from Salesforce-based CRM to proprietary Vault CRM.
Q4 Earnings Growth
Company reports advancing income and robust demand for Vault platform.
IPO Launch
Veeva Systems goes public, establishing the vertical SaaS model for life sciences.
Veeva Systems remains a dominant force in the life sciences cloud sector, boasting a 13.6% CAGR since its 2013 IPO and a client list including 15 of the top 20 biopharma firms. While revenue growth is moderating as the company matures, its $20 billion total addressable market and high switching costs suggest significant long-term compounding potential.
Veeva Systems remains a cornerstone of the life sciences cloud, targeting a $6 billion revenue run rate by 2030. Despite recent competitive pressures and a strategic migration to its proprietary Vault CRM, the company’s deep integration with 15 of the top 20 biopharma firms provides a robust long-term growth foundation.
As market volatility persists in early 2026, Eli Lilly and Veeva Systems emerge as top growth picks driven by the obesity drug boom and AI integration. With Eli Lilly's tirzepatide securing its spot as the world's top-selling drug and new oral GLP-1s on the horizon, the pharmaceutical landscape is shifting toward tech-heavy, high-margin innovation.